Effect of Nitric Oxide Donors on Neointima Formation and Vascular Reactivity in the Collared Carotid Artery of Rabbits

Guido R. Y. De Meyer, Hidde Bult, *Levent Üstünes, †Mark M. Kockx, ‡Martin Feelisch, and Arnold G. Herman

Division of Pharmacology, University of Antwerp, Antwerp; *Department of Pharmacology, Faculty of Pharmacy, Ege University, Izmir, Turkey; †Department of Pathology, General Hospital Middelheim, Antwerp, Belgium; and ‡Department of Nitric Oxide Research, Schwarz Pharma, Monheim, Germany

**Summary:** Intimal thickening in arteries is considered a site of predilection for atherosclerosis. We investigated whether oral application of the nitric oxide (NO) donors SPM-5185 (N-nitrosovalyl-5-(N'-acetylalanyl) cysteine ethylester, 10 mg/kg body weight twice daily (b.i.d.)) and molsidomine (10 mg/kg body weight/day) can retard neointima formation and changes in vascular reactivity induced by a nonocclusive, soft silicone collar positioned around the left carotid artery of rabbits. The contralateral carotid artery was sham operated and served as a control. Drug and placebo (diet without drug) treatments were initiated 7 days before placement of the collar. At the end of the experiments, two segments were cut from each collared and sham-treated artery, one for measurement of the cross-sectional area of intima and media and the other for isometric tension recording. Sham treatment did not result in intimal thickening in either group. In contrast, the intima/media (I/M) ratio was considerably increased after 14 days of collar treatment as a result of neointima formation. Intimal thickening was significantly inhibited by SPM-5185 (I/M ratio 0.05 ± 0.01 vs. 0.11 ± 0.02, p < 0.05), but not by molsidomine (0.06 ± 0.02 vs. 0.08 ± 0.02, p = 0.49), which is a donor of both NO and superoxide anions. Neither collar nor NO donor treatment altered the area of the media. SPM-5185 did not alter the percentage of replicating smooth muscle cells (SMC) in the media after collar treatment, as demonstrated by their immunoreactivity for proliferating cell nuclear antigen (PCNA). Neointima formation was associated with a decreased sensitivity to acetylcholine (ACH), an increased sensitivity to 5-hydroxytryptamine (5-HT), and a decreased maximum force development to 5-HT and KCl. Despite the significant reduction of intimal thickening, SPM-5185 did not antagonize these collar-induced modifications in vascular reactivity, although a tendency toward normalization of the pD2 value of ACh in collared arteries was observed. Moreover, SPM-5185 did not lead to cross-tolerance towards nitroglycerin (NTG). Development of a neointima can be inhibited by the NO-donor SPM-5185. Key Words: Atherosclerosis—Intima—Endothelium—Nitric oxide—5-Hydroxytryptamine—SPM-5185—Molsidomine.

An early and essential step in the development of atherosclerosis is thickening of the intima. At birth, the arterial wall of human arteries is covered with endothelial cells (EC), which rest directly on the internal elastic membrane. This elastic lamina demarcates the EC from the smooth muscle cells (SMC) of the media. Early in life, however, SMC appear between the EC and the internal elastic membrane of large arteries. In contrast to their normal circular orientation in the media, these cells lie in a longitudinal direction, with collagen and elastic fibers between them. In this way, a thickening of the intima is formed. This so-called neointima is a site of predilection for atherosclerosis (1,2).

In an attempt to develop a suitable animal model that mimics these vascular changes, several methods have been applied to produce neointima formation. They can be divided into two categories: those that use intraluminal and those that use perivascular manipulation. An example of the former is denudation of the EC with a balloon catheter; an example of the latter is the positioning of a nonocclusive,
soft and flexible silicone collar around the rabbit carotid artery, resulting in the generation of a neointima in 1 week (3.4). The perivascular collar placement has the particular advantage of avoiding direct injury to the endothelium (5).

It has been reported (6-8) that chemically dissimilar nitric oxide (NO)-generating (9) drugs concentration-dependently inhibit DNA synthesis and proliferation of rat and rabbit aortic SMC in culture and that their antiinmogenic effect was mimicked by 8-bromo-cyclic GMP. These effects were independent of a cellular damage. Therefore, NO was suggested as a modulator of vascular SMC mitogenesis and proliferation, acting through a cyclic GMP-mediated mechanism. In the present study, we used both molsidomine, which releases NO spontaneously (10), and a novel type of NO donor, SPM-5185 (N-nitrotopivaloyl)-5-(3-acetylaminocarbonyl)-cysteine ethylster). The advantage of the latter agent is that it contains both a nitrate ester and a thiol, in casu cysteine, in a single molecule (11). In view of these observations, our objectives in the present in vivo study were to determine whether the collagen-induced neointima formation can be prevented or retarded by treatment with an NO donor and whether exogenous NO supplementation can overcome the modifications in vascular reactivity associated with neointima formation.

METHODS

Treatmen

Experiment 1. After 7 days of quarantine, 24 male New Zealand white rabbits weighing 2.5-3.5 kg were randomly divided into two groups. The treatment group received SPM-5185 at a dose of 10 mg/kg body weight twice daily (b.i.d.) with the drinking water. The drug was freshly dissolved in 150 ml drinking water and was given to the rabbits in the morning and in the evening. A placebo group received the same volume of drinking water without the drug. Previous experiments showed that this volume (300 ml) supplied the daily need of drinking water of our rabbits. Throughout the experiment, rabbits were housed in individual cages and had ad libitum access to food.

Experiment 2. After 7 days of quarantine, 16 male New Zealand white rabbits weighing 2.5-3.5 kg were divided into two groups, which received diets (150 g/day) containing molsidomine 0 or 200 mg/kg chow. This resulted in doses of molsidomine of 0 and 10 mg/kg body weight/day, respectively. Throughout the experiment, rabbits were housed in individual cages and had ad libitum access to water.

The doses of molsidomine and SPM-5185 were selected because they were equivalent on a gram per kilogram of body weight basis. Rabbits require ~100 times more molsidomine than humans to induce a decrease in blood pressure (BP) (J. Ostrowski, unpublished observation). Therefore, the 10 mg/kg/day was equivalent to the dose used in the clinic. The half-life (τ) of SPM-5185 in rabbits is not known. The dose of SPM-5185 was chosen in analogy with that of molsidomine.

Induction of neointima

After 7 days of treatment with or without the NO donor, the rabbits were anesthetized with sodium pentobarbital 30 mg/kg (i.p.). Subsequently, the left carotid artery was freed and surrounded by a nonocclusive, flexible silicone collar 2.2 cm long (3.12-14). The right carotid artery was sham operated, i.e., separated from its connective tissue by blunt dissection, receiving a stretch similar to that used for the contralateral collared artery. The carotid arteries were then returned to their original position, and the wounds were sutured. After recovery from anesthesia, the rabbits received their respective treatment for 1 (experiment 2) or 2 (experiment 1) weeks.

 Morphometry

The rabbits were killed with sodium pentobarbital, and two segments (3 mm) were cut from both the collared and sham-operated artery, one for morphometry and the other one for isometric tension recording (described herein). The former was immediately placed in methacarn fixative (methanol:1,1,1-trichloroethane:glacial acetic acid, 60:30:10 by volume) for 24 h, and dehydrated in a graded series of isopropyl alcohol (60-100%) followed by toluol before being embedded in paraffin. Transverse sections were cut and stained with Sirius red hematoxylin. The cross-sectional area of lumen, neointima, and media was measured with the Osteomeasure package (Osteo Metrics, Atlanta, GA, U.S.A.) by an independent observer who was unaware of the treatment. Furthermore, the intima/media (I/M) ratio of the artery was calculated.

For the immunohistochemical staining of proliferating cell nuclear antigen (PCNA) a PC10 cyclic mouse monoclonal antibody (MoAb; Dako, Glostrup, Denmark) was used at a 1:10 dilution. The MoAb was diluted in phosphate-buffered saline (PBS). After three washes with PBS, the sections were incubated with rabbit anti-mouse peroxidase for 45 min. For the demonstration of the complex, 3-amin-9-ethylcarbazole was used as a chromogen. For negative controls, the primary antibody was omitted (4). The PCNA immunoreactive SMC nuclei in the media and intima, total number of SMC nuclei in the media were counted using a projection microscope. The PCNA activity was expressed as the percentage of PCNA-positive SMC nuclei per total number of medial SMC nuclei (4).

Vascular reactivity

The ring segments were immediately placed in physiological salt solution (PSS) and, after being cleaned of loose connective tissue, were mounted in organ chambers filled with 25 ml PSS maintained at 37°C, and continuously gassed with 95% O2/5% CO2 (12-14). Tension was measured isometrically with a Statham UC2 force transducer. After 15 min equilibration, the preparations were gradually stretched up to a force of 7 g to bring the segments to the optimal point of their length-tension relationship. The rings were then allowed to equilibrate for 45 min more at their optimal length. During this period, the bath solution was changed every 15 min. Indomethacin (3 × 10^-6 M) was added to block prostaglandin biosynthesis.

In the first experiment, the rings were exposed to a cumulative (0.5 log unit) concentration range of 5-hydroxytryptamine (5-HT, 3 × 10^-10-3 × 10^-6 M). After
reaching maximum contraction, the rings were consecu-
tively exposed to \(3 \times 10^{-7} \text{ M}, 3 \times 10^{-6} \text{ M}, \) and \(3 \times 10^{-5} \text{ M}\) nitroglycerin (NTG). After washing, the rings were
again contracted with phenylephrine (PE \(3.5 \times 10^{-7} \text{ M}\)) and
cumulative (0.5 log unit) concentration–relaxation curves
were performed for acetylcholine (ACH \(3 \times 10^{-7} \text{ to} \times 10^{-5} \text{ M}\)). After final washing, the maximum contrac-
tile force was determined at the end of the experiment
by exposure of the tissues to \(120 \text{ mM KCl}\) (15). In the second
experiment, the rings were contracted with PE \(3.5 \times 10^{-7} \text{ M}\). Cumulative concentration–response curves were
constructed for ACH (\(10^{-7} \text{ to} \times 10^{-5} \text{ M}\)) and SIN-1
\(10^{-9} \text{ to} \times 10^{-5} \text{ M}\), the NO-releasing metabolite of
molsidomine. The bath medium was exchanged three
times between the addition of agonists, and tissues were
allowed to equilibrate for 30 min.

**BP measurements**

Acute drug treatment (intraocular). Rabbits were
anesthetized, and the BP was measured. Thereafter,
the animals received either an intravenous bolus injection of
a mg SPM-5185/kg body weight followed by an intrave-
nous infusion of 2 mg SPM-5185/kg body weight/h or were
treated with saline. The BP was measured after 30-min

treatment.

Long-term drug treatment (oral). The BP of the molsi-
domine-treated (10 mg/kg body weight/day orally) and
the respective control rabbits was measured in the con-
scious state after 7 day treatment, 3 h after the last ad-
ministration. In a separate experiment, we measured the
BP of 6 conscious rabbits before and after oral treatment
with SPM-5185 (10 mg/kg body weight, b.i.d.) for 7 days,
18 h after the last administration.

In all cases, the BP was measured with a Statham
P2310 pressure transducer connected to an HP 8805S car-
rier amplifier. For this purpose, the skin of the ear of
the rabbits was disinfected and sprayed with lidocaine (10%
solution, Astra Nobelpharma, Brussels, Belgium) and a
22-gauge cannula was inserted in the central ear artery,
using transillumination.

**Materials**

The normal rabbit chow (Altromin 2023), and the molsi-
domine-containing chow (200 mg/kg) were prepared by
and obtained from Altromin (Lage, Germany). The PSS
contained (in mM): NaCl 118, KCl 4.7, CaCl\(_2\) 2.5,
KH\(_2\)PO\(_4\) 1.2, MgSO\(_4\) 1.2, NaHCO\(_3\) 25, and glucose 11.1.
ACH chloride and 5-HT were obtained from Sigma (St.
Louis, MO, U.S.A.). NTG was purchased as commercial
aqueous solution from Merck (Darmstadt, Germany), in-
domethacin sodium tetrahydrate from Merck, Sharp &
Dohme (München, Germany), and sodium pentobarbital
from Phynpsic (Brussels, Belgium). SPM-5185 was ob-
tained from Schwarz Pharma (Monheim, Germany), and
SIN-1 and molsidomine were obtained from Therabel Re-
search (Brussels, Belgium). Silicone (Silastic E, Dow
Corning) was provided by the Compagnie Commerciale
de Matière Premières (Antwerp, Belgium). 5-HT was dis-
solved in an aqueous solution of ascorbic acid (0.01%) and
diluted in distilled water. The other drugs were made up
in distilled water.

**Data analysis**

All data are mean ± SEM. The number of arteries re-
ported (n) equals the number of rabbits used. For the
statistical analysis, the SPSS/PC\(^*\) package (SPSS, Chi-
icago, IL, U.S.A.) was applied. A 5% level of significance
was selected. To compare the I/M ratio, areas of intima
and media, and the percentage of PCNA-positive SMC
nuclei of the media between placebo and NO donor
groups, we used the Mann-Whitney U test. The effect of
the collagen treatment (i.e., sham vs. collagen) was evaluated
in each group by the Wilcoxon matched-pairs signed-
ranks test. Effects on BP were evaluated by Student’s t

test.

Relaxations were expressed as percentage of the initial
contraction. The negative logarithm of the molar concen-
tration of agonist that produced a half-maximal contrac-
tion for that agonist (\(-\log EC\(_{50}\) or pD\(_2\)) was determined for
each segment by linear regression. These data were eval-
uated statistically by a factorial analysis of variance
(ANOVA) with drug treatment (two levels, NO donor or
placebo) as between-rabbit factor and collagen (two levels,
present or not) as within-rabbit factor.

**RESULTS**

**Morphometric analysis of neointima formation**

Placebo groups. The area of the intima and the I/M ratio were significantly increased after the po-
sitioning of the silicone collar as compared with the sham
operation. In contrast, the area of the media had not changed after collar application (Figs. 1 and 2).

Treatment groups. A neointima had developed after
collar placement in all treatment groups. How-

ever, both the intimal area and the I/M ratio were
significantly lower in the SPM-5185 group (Fig. 1).
Molsidomine tended to decrease cross-sectional
area of intima and the I/M ratio, but the effect was
not statistically significant (Fig. 2). Neither the col-
lar nor the SPM-5185 or molsidomine treatments
significantly altered the area of the media (Figs. 1 and 2).

**PCNA activity in the media**

In the sham-treated carotid arteries, the percent-
age of replicating medial SMC amounted to 0.18 ±
0.07% in the placebo group, and was increased to
0.54 ± 0.16% in the SPM-5185 group. In the col-
larred arteries, a higher percentage (1.53 ± 0.68%)
of the medial SMC was PCNA-positive in the placebo
group. The tendency to reduction (1.14 ± 0.40%) in
the SPM-5185 group was not statistically signifi-
cant.

**Vascular reactivity**

\(5-HT\). 5-HT (\(3 \times 10^{-6} - 3 \times 10^{-6} \text{ M}\)) induced
concentration-dependent contractions in sham and
collar-treated segments from all groups. The maxi-
mum contractile response (\(E\(_{max}\)) to 5-HT in collar-
treated rings was always slightly but significantly
diminished as compared with that in sham-treated
rings. The treatment with SPM-5185 (Table 1), or
molsidomine (data not shown) did not affect these
maximum contractions in either sham or collared
rings.
7.15 ± 0.03 to 7.61 ± 0.12 in the SPM-5185 group, p < 0.001). The treatments with SPM-5185 or molsidomine (data not shown) did not affect the pD₂ values in either sham or collar-treated rings.

KCl. KCl (120 mM) contracted sham and collared rings from both treatment groups, but the response was significantly diminished in collar-treated rings.

FIG. 1. Effect of the nitric oxide (NO) donor SPM-5185 on neointimal formation in the rabbit carotid artery induced by 14-day collar treatment. SPM-5185 was administered twice daily for 21 days in the drinking water at a dose of 10 mg/kg body weight, beginning 7 days before collar placement. A: Cross-sectional areas of the intima (segments measured in triplicate; distance between sections 250 μm). B: Cross-sectional areas of the media (segments measured in triplicate). C: Intima/media ratio (calculated from measurement in triplicate). Data are mean ± SEM. *p < 0.05, **p < 0.01 sham versus collar (Wilcoxon matched-pairs signed-ranks test), and tp < 0.05 placebo versus SPM-5185 (Mann-Whitney U test).

On the other hand, the presence of the collar led to an increased sensitivity of the artery to 5-HT in both placebo- and SPM-5185-treated groups, as concluded from the increased pD₂ values (from 7.16 ± 0.01 to 7.64 ± 0.12 in the placebo group and from 7.15 ± 0.03 to 7.61 ± 0.12 in the SPM-5185 group, p < 0.001). The treatments with SPM-5185 or molsidomine (data not shown) did not affect the pD₂ values in either sham or collar-treated rings.

KCl. KCl (120 mM) contracted sham and collared rings from both treatment groups, but the response was significantly diminished in collar-treated rings.

FIG. 2. Effect of molsidomine on neointimal formation in the rabbit carotid artery induced by 7-day collar treatment. Molsidomine was administered for 14 days in the diet at a dose of 10 mg/kg body weight/day, beginning 7 days before collar placement. A: Cross-sectional areas of the intima (segments measured in quintuplicate). B: Cross-sectional areas of the media (segments measured in quintuplicate). C: Intima/media ratio (calculated from measurement in quintuplicate). Data are mean ± SEM. ***p < 0.001 sham versus collar (Wilcoxon matched-pairs signed-ranks test).

TABLE 1. 5-HT-, KCl-, and PE-induced contraction (g) of rabbit carotid arteries without and with a silicone collar positioned for 14 days in placebo- and SPM-5185-treated rabbits

<table>
<thead>
<tr>
<th>Condition</th>
<th>5-HT 3 × 10⁻⁶M</th>
<th>KCl 120 mM</th>
<th>PE 3.5 × 10⁻⁷M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n = 8)</td>
<td>9.1 ± 0.5</td>
<td>11.0 ± 0.9</td>
<td>9.9 ± 0.5</td>
</tr>
<tr>
<td>SPM-5185 (n = 7)</td>
<td>9.5 ± 0.6</td>
<td>11.1 ± 1.0</td>
<td>10.1 ± 0.8</td>
</tr>
</tbody>
</table>

5-HT, 5-hydroxytryptamine; PE, phenylephrine.
Data are mean ± SEM.
* p < 0.01 versus sham; † p < 0.05 versus sham.

SPM-5185 did not affect force development to KCl in either sham or collar-treated rings (Table 1).

**Initial contraction to PE**

The contractile response to PE (3.5 × 10⁻⁷M) in collar-treated rings was significantly diminished as compared with that of sham-treated rings (Table 1). The treatment with SPM-5185 or molsidomine (results not shown) did not affect the contraction to PE in either sham or collar-treated rings.

ACh (3 × 10⁻⁹–10⁻⁶ M) induced concentration-dependent relaxations of sham and collar-treated segments of the rabbit carotid artery after contraction with phenylephrine (3.5 × 10⁻⁷M). The maximum extent of relaxation was decreased in the collar segments of both treatment groups (from 76 ± 40 to 45 ± 4% in the placebo group and from 76 ± 5 to 70 ± 8% in the SPM-5185 group). SPM-5185 and molsidomine (data not shown) did not alter the maximum relaxation in response to ACh in sham or collar arteries.

Furthermore, the presence of the collar led to a decreased sensitivity of the arterial segment to ACh both in placebo and SPM-5185- or molsidomine-treated groups, as concluded from the decrease in pD₂ values. SPM-5185, but not molsidomine, tended to normalize pD₂ values in collar rings (Table 2).

**NTG and SIN-1.** NTG (3 × 10⁻⁹, 3 × 10⁻⁸, and 3 × 10⁻⁷ M) induced concentration-dependent relaxations in sham and collar-treated segments precontracted with 5-HT 3 × 10⁻⁶ M. The percentage of relaxation to increasing concentrations of NTG was significantly reduced in collar-treated rings as compared with sham rings (Table 3). The treatment with SPM-5185 did not influence the extent of these relaxations in either sham or collared rings (Table 3).

SIN-1 evoked complete relaxation of the sham-operated segments contracted with PE. However, in collared segments, the maximum percentage of relaxation was slightly diminished (from 98 ± 1 to 95 ± 3% in the placebo group and from 97 ± 2 to 90 ± 4% in the molsidomine group, p = 0.026). The pD₂ was not significantly altered by either the collar or the molsidomine treatment (6.46 ± 0.09 in sham and 6.35 ± 0.11 in collar vessels of the placebo group and 6.19 ± 0.12 in sham and 6.26 ± 0.21 in collar segments of the molsidomine group).

**BP**

When SPM-5185 was administered acutely to rabbits (1 mg/kg i.v. bolus injection + 2 mg/kg/h i.v. infusion) mean arterial BP (MAP) decreased from 100 ± 8 to 82 ± 7 mm Hg after 30 min, whereas BP did not change in saline-treated rabbits. Similar results were obtained with molsidomine (data not shown).

SPM-5185 administered orally to rabbits, induced a paradoxical increase in MAP after 1-week treatment (80 ± 1 mm Hg before and 90 ± 2 mm Hg after SPM-5185, p < 0.01). Molsidomine did not affect MAP significantly (97 ± 4 mm Hg in the placebo group vs. 90 ± 3 mm Hg in the molsidomine-treated group).

**DISCUSSION**

Classic organic nitrates have been reported to promote as well as to inhibit cell proliferation (6,16). Therefore, we wished to investigate the effect of two structurally unrelated NO donor compounds, molsidomine and SPM-5185, on the development of a neointima in vivo. SPM-5185 is a novel, nitrate-based NO donor that liberates NO indirectly after cleavage of its thioether function and reduction of the nitrate group. Depletion of reduced thiols has been implicated in the development of tolerance to classic organic nitrates such as NTG and isosorbide dinitrate (17). Because SPM-5185 contains a cysteine moiety in the same molecule, thiol depletion and development of nitrate tolerance are circum-

TABLE 3. NTG-induced relaxation (% of 5-HT (3 × 10⁻⁴M)-contracted rabbit carotid arteries without and with a silicone collar positioned for 14 days in placebo- and SPM-5185-treated rabbits

<table>
<thead>
<tr>
<th>Condition</th>
<th>NTG 3 × 10⁻⁴M</th>
<th>NTG 3 × 10⁻⁴M</th>
<th>NTG 3 × 10⁻⁴M</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sham</td>
<td>Collar</td>
<td>Sham</td>
</tr>
<tr>
<td>Placebo (n = 8)</td>
<td>4 ± 1</td>
<td>3 ± 1</td>
<td>18 ± 2</td>
</tr>
<tr>
<td>SPM-5185 (n = 7)</td>
<td>4 ± 1</td>
<td>2 ± 1</td>
<td>19 ± 4</td>
</tr>
</tbody>
</table>

NTG, nitroglycerine; 5-HT, 5-hydroxytryptamine.
Data are mean ± SEM.
* p < 0.05 versus sham.

vented with this NO donor. SIN-1, the active metabolite of molsidomine, belongs to the class of synergonines, compounds that liberate NO spontaneously, i.e., independent of the presence of thiol groups. However, with each molecule of NO released, one molecule of oxygen is reduced to superoxide anion (10). Therefore, SIN-1 is not only a donor of NO, but of superoxide as well. Both types of NO donors were tested in a rabbit model in which intimal thickening is induced by the positioning of a silicone collar around the carotid artery. The positioning of the collar led to neointima formation, as previously described (3,4,13). SPM-5185 profoundly decreased intimal thickening, as characterized by a significant reduction in both cross-sectional area of intima and I/M ratio. This result is consistent with the observation that chronic inhibition of NO production accelerates neointima formation in hypercholesterolemic rabbits (18). Therefore, the effect of SPM-5185 is likely due to its NO-generating capacity.

To evaluate whether mere hemodynamic effects on the vascular wall may have influenced intimal thickening (19), we measured systemic arterial BP in rabbits from both placebo and treatment groups. The main conclusion that can be drawn from these BP measurements is that the inhibition of intimal thickening is not due to BP-lowering effects of the NO donors. Whereas both NO donors decreased MAP when administered intravenously to anesthetized rabbits, no such effect was noted during long-term oral treatment with the compounds in conscious rabbits. After 7 days of oral treatment, molsidomine had no significant effect on MAP of conscious rabbits, whereas SPM-5185 slightly increased rather than decreased MAP. The lack of a decrease in BP may be explained by the fact that the last dose of molsidomine and of SPM-5185 were given 3 and 18 h, respectively, before BP was measured, by which time the maximal depressor effects may well have disappeared. The increase in arterial BP observed 18 h after the last treatment with SPM-5185 may be due to (a) a type I error of the statistical test of the small samples, or (b) a rebound effect (20–22) due to repeated activation of neurohumoral systems [sympathoadrenal axis, renin–angiotensin system (RAS)] (23), and/or intravascular volume expansion. Indeed, NO donors may not only produce direct peripheral arterial and venous dilatation but also activate compensatory mechanisms that cause arterial and venous peripheral vasocstriction. The hemodynamic effects of an NO donor are therefore the result of two interacting factors: the rapid but short-lived direct vasodilating effects and the secondary activation of counteractive mechanisms provoked by the reduction in arterial BP. With abrupt discontinuation of an NO donor, the vasodilator component rapidly disappears, leaving the vasocostrictive mechanisms unopposed. A rebound phenomenon has been described for SPM-5185 in dog coronary circulation (24). Abukhrees and colleagues (23) demonstrated that BP rebounded to hypertensive levels after the intravenous infusion of sodium nitroprusside in conscious rats and that this rebound appeared to be mediated by the RAS. Moreover, we recently demonstrated that although three different ACE-inhibitors all significantly decreased MAP in conscious rabbits, none of them altered collar-induced intimal thickening (G. R. Y. De Meyer, unpublished observations). Clearly, the inhibition of intimal thickening observed with SPM-5185 cannot be explained by a reduction in the BP.

Although SPM-5185 significantly decreased the collar-induced neointima, it did not reduce SMC replication in the media. In the media of sham-operated arteries, SPM-5185 instead increased the percentage of PCNA-positive SMC. Therefore, the reduction in neointima formation induced by SPM-5185 may be due to inhibition of migration rather than proliferation of SMC. Indeed, induction of SMC replication and migration are not necessarily causally related events in the vessel wall (4,25). Migration appears to be the initial event in the neointima formation in the collar model. The other possibility, that neointimal cells are descendants of pre-existing intimal cells is unlikely, since there are very few resident subendothelial SMC in control carotid arteries (4).

Because molsidomine did not have a significant effect on either BP or neointima formation, plasma levels of this drug, owing to pharmacokinetic factors, may not have been sufficiently high to provide continuous NO generation in the vasculature. How-
ever, in a parallel experiment with the thoracic aorta of the same rabbits, molsidomine slightly decreased the maximum amplitude of ACh- and calcium ionophore (A23187)-induced relaxations and rendered the SMC less sensitive to SIN-1 without influencing maximum relaxation. Although the treatment period of the present investigation was only 2 weeks, our findings for that period are in agreement with the outcome of a previous experiment that lasted 16 weeks (26,27). Therefore, molsidomine appeared to be active. The lack of significant effect of molsidomine on intimal thickening may be explained by the fact that NO release from molsidomine is accompanied by the production of superoxide anion, which can react with NO to yield peroxynitrite, which decomposes to form the highly reactive hydroxyl radical (9). We previously demonstrated increased contents of 13-hydroxyoctadecadienoic acid and 15-1-hydroxyicosatetraenoic acid, metabolites of the peroxides of linoleic acid and arachidonic acid, in the thoracic aorta of molsidomine-treated rabbits (28).

In accordance with results of previous studies in our laboratory, collar decreased the E_max of 5-HT and KCl (15) and increased the sensitivity to 5-HT (12,15). Despite a significant reduction in intimal thickening, SPM-5185 could not overcome these changes in vascular reactivity. Two possible explanations are conceivable for this apparent discrepancy: (a) The reduction of the development of a neointima by SPM-5185 was not sufficient to alter the 5-HT-related modifications in vascular reactivity; and (b) the modifications in vascular reactivity in response to 5-HT are not dependent on the extent of neointima formation. Indeed, the sensitization to 5-HT after 1-week treatment is of the same magnitude as that after 2 weeks, although the development of the neointima is still incomplete (4). Therefore, the sensitization to 5-HT apparently is independent of the extent of intimal thickening.

Tolerance to organic nitrates in humans has been recognized for >100 years as a pharmacological phenomenon (29). Several reports showed the existence of tolerance in experimental animals in vivo (30-32). Furthermore, tolerance in isolated vascular SMC from animals made tolerant to organic nitrate esters has been reported (33,34). To prove that SPM-5185 did not induce cross-tolerance toward NTG, carotid arterial segments were exposed to three concentrations of the latter drug. The results confirmed that the semichronic treatment with the long acting nitrate SPM-5185 induced no sign of cross-tolerance toward NTG in either sham or collar-treated rings. Similarly, semichronic treatment with molsidomine did not induce tolerance toward SIN-1 in either sham or collared carotid arteries.

ACh was used to induce relaxation of the segments precontracted with PE 3.5 × 10^-7M by stimulation of the endothelial arginine-NO system. The collar decreased the sensitivity of the artery to ACh, a finding consistent with previous reports (13, 14,35). However, neither the pD_2 value of ACh nor the maximum percentage relaxation was significantly affected by the SPM-5185 or molsidomine treatment in normal or collared carotid arteries, suggesting that the treatments with these NO donors did not alter the capacity of the endothelium of the carotid artery to generate NO in response to muscarinic receptor stimulation. However, there was a tendency toward normalization of the pD_2 value of ACh in the collared arteries of the SPM-5185-treated group, which is in accord with the data of Schwarz and co-workers (36). The contractile response to PE (3.5 × 10^-7M) in collar-treated rings was significantly diminished as compared with that in sham-treated rings. A decrease in initial contractile strength lead to an enhanced sensitivity to vasodilators (37). However, intima-bearing arteries were less sensitive to ACh. Moreover, treatment with the NO donors did not affect the contraction to PE in either sham or collar-treated rings. Therefore, the tendency toward normalization of the pD_2 value of ACh in the collared arteries of the SPM-5185-treated group as compared with the placebo group cannot be explained by a decrease in the initial contraction to PE.

Our results demonstrate that the administration of an NO-donor can inhibit neointima formation in vivo, confirming the results of Guo and associates (38), who demonstrated a reduction of intimal thickening by SPM-5185 in a rat carotid artery injury model. Furthermore, our results demonstrate that SPM-5185 is active when administered orally, which is an advantage over most of the newer NO donors so far reported in the literature. Moreover, the drug is not prone to rapid tolerance development and did not lead to cross-tolerance toward NTG. Despite the significant reduction observed in the development of a neointima, SPM-5185 did not significantly antagonize the collar-induced reduction of the maximum contractile response to 5-HT and KCl. Therefore, the maximal contractile response of collared vessels is not dependent on the thickness of the neointima. In contrast, the pD_2 value of ACh tended to normalize in collared arteries of the SPM-5185-treated group. That exogenous NO can modulate the formation of a neointima in vivo may have important implications not only for our understanding of the pathophysiology of atherosclerosis but also possibly for future antiatherosclerotic therapy.

Acknowledgment. This work was supported by Grant No. 9.006.91 of the Belgian Fund for Medical Scientific Research and by the Belgian Programme on Interuniversity Poles of Attraction by the Belgian State, Prime Minister's Office, Science Policy Programming. We thank Liliane Van den Eynde and Lydie Van Laerhoven for typing the manuscript and Hermine Fret, Rita Van den
REFERENCES

1. Wilm S. L. The nature of diffuse intimal thickening of arter-

2. Stary HC, Blankenhorn DH, Chandler AB, et al. A defin-
tion of the intima of human arteries and of its atheroscle-

sclerotic lesions in the rabbit carotid artery induced by perivascular manipula-

4. Kockx MM, De Meyer GRY, Jacob WA, Bult H, Herman AG. Trigeminal sequence of neointima formation in the

5. Kockx MM, De Meyer GRY, Andries LJ, Bult H, Jacob WA, Herman AG. The endothelium during cufl-induced

6. Gug UC, Hassad A. Nitric oxide generating vasodilators and
B-bromo-cyclic guanosine monophosphate inhibit mi-
genesis and proliferation of cultured rat vascular smooth

Antiproliferative action of cyclic GMP-elevating vasodila-
tors in cultured rabbit aortic smooth muscle cells. Atheros-
cler usis 1989;88:143-7.

8. Nakada T, Nakayama M, Kato R. Inhibition by nitric oxide
and nitric oxide-producing vasodilators of DNA synthesis in
vascular smooth muscle cells. Eur J Pharmacol 1990;189:
347-53.

9. Fiehe M. The biochemical pathways of nitric oxide for-
mation from nitrovasodilators: appropriate choice of exoge-
nous NO donors and aspects of preparation and handling of
appropriate NO solutions. J Cardiovasc Pharmacol 1991;

10. Fiehe M, Ostrowski J, Noack E. On the mechanism of

11. Siegfried MR, Carey C, Ma XL, Lefer AM. Beneficial ef-
fects of SPM-5185, a cysteine-containing NO donor in myo-

cardial ischemia-reperfusion. Am J Physiol 1992;263:
H771-7.

12. De Meyer GRY, Bult H, Martin FJ, Van Hoydonck A-E, Herman AG. The effect of a developing neointima on sero-
tonergic and adrenergic contractions. Eur J Pharmacol 1990;

13. De Meyer GRY, Bult H, Van Hoydonck A-E, Jordans FH,
Buysens N, Herman AG. Neointima formation impairs en-
thoeliasal muscarinic receptors while enhancing prostacyclin-

14. De Meyer GRY, Bult H, Herman AG. Selective muscarinic
alterations of nitric oxide-mediated relaxations by neoin-

15. De Meyer GRY, Bult H, Ustilins L, Kockx MM, Jordans FH,
Zonnekeyn LL, Herman AG. Vasocostrinctor responses
after neointima formation and endothelial denuda-
tion in the rabbit carotid artery. Br J Pharmacol 1994;112:
471-6.

16. O'Connor KJ, Knowles RG, Patel KD. Nitrovasodilators
have proliferative as well as antiproliferative effects. J Car-

17. Needham P, Johnson EM Jr. Mechanism of tolerance de-
velopment to organic nitrates. J Pharmacol Exp Ther 1973;

18. Cayatte AJ, Palacino JJ, Horton K, Cohen RA. Chronic in-
hibition of nitric oxide production accelerates neointima for-
mation and impairs endothelial function in hypercholester-

19. Herrmans WRM, Rensing BJ, Strauss BH, Serruys W. Pre-
vention of restenosis after percutaneous transluminal coro-

20. Packer M, Miller J, Medina N, Gorlin R, Herrman MV. Re-
bound hemodynamic events after the abrupt withdrawal of

21. Oliviari MT, Carlyle PF, Levine TB, Cohn JN. Hemody-
namic and hormonal response to transdermal nitroglycerin
in normal subjects and in patients with congestive heart fail-

22. Packer M, Medina N, Yushak M, Lee WH. Hemodynamic
factors limiting the response to transdermal nitroglycerin in
severe chronic congestive heart failure. Am J Cardiol 1986;

23. Abukhrees MM, Ertel RJ, Dixit BN, Volmer RR. Role of the
renin-angiotensin system in the blood pressure rebound to

are potent dilators of large coronary arteries with reduced
development of tolerance during long-term infusion in dogs:

25. Clowes AW, Schwartz SM. Significance of quiescent
smooth muscle migration in the injured rat carotid artery.

nitric oxide on EDRF release by aortae from normal and

27. Bult H, De Meyer GRY, Jordans FH, Herman AG. Chronic
exposure to exogenous nitric oxide may suppress its endog-
17(suppl 3):S79-82.

28. De Meyer GRY, Bult H, Herman AG. Early atherosclerosis
is accompanied by a decreased rather than an increased ac-

29. Stewart DD. Remarkable tolerance to nitroglycerin. Phila-
delphia Polyclinl 1886;172.

30. Bogaert MG. Tolerance towards glyceryl trinitrate (trinitrin)

31. Bogaert MG, De Schep德ryder AT. Tolerance towards

32. Clark DG, Litchfield MG. Metabolism of ethylene glycol
dinitrate (ethylene dinitrate) in the rat following repeated


34. Herman AG, Bogaert MG. Tolerance at the level of the
vascular smooth muscle. Arch Int Pharmacodyn 1971;192:
206-2.

35. Arthur JF, Dusting GJ. Selective endothelial dysfunction in

endothelium-dependent vasodilation by low-dose nitroglyc-

37. Furchgott RF. Role of endothelium in responses of vascular

38. Guo J, Milhaud KA, Tuan RS, Lefer AM. Beneficial effect of
SPM-5185, a cysteine-containing nitric oxide donor, in rat
